Publications by authors named "Augustina Culinescu"
Background And Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
View Article and Find Full Text PDFArticle Synopsis
- Pegylated interferon alpha 2a is still used to treat chronic hepatitis D, showing a virologic response of 17-47% but with over 50% of patients experiencing relapses.
- In a study of 76 patients under a Romanian protocol, treatment typically lasted 48 to 96 weeks, with specific criteria for stopping and restarting based on viral load changes.
- Out of the monitored patients, 35.5% showed significant viral load reduction after 6 months, with a subset achieving undetectable levels for at least 24 weeks post-treatment, while moderate adverse reactions were common.